Companies managing drug benefits would become more transparent in Medicare and Medicaid.
Companies that manage prescription drug benefits (PBMs) would become more transparent about drug pricing and payments in Medicaid and Medicare under this bill. It aims to ensure pharmacies are paid fairly and that patients have better access to their medications, by changing how these companies operate and report their finances. These changes would affect how drug costs are determined and paid for millions of Americans.
Today, Pharmacy Benefit Managers (PBMs) often operate with limited transparency in how they negotiate drug prices and pay pharmacies. This can lead to practices like "spread pricing." After this bill, PBMs would need to be much more transparent about their finances and payment models in Medicaid and Medicare. This includes passing through rebates and using clear, flat fees. This would also mean more oversight and reporting requirements for PBMs, and more choices for Medicare patients in where they fill their prescriptions.
S 3345 · 119th Congress · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
32 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.